StreetInsider.com News Articles

Form 6-K Clearmind Medicine Inc. For: Jun 01

Mon, 01 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26583516.html

Form 6-K Clearmind Medicine Inc. For: Jun 01

Mon, 01 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26583516.html

Clearmind Medicine files Japanese patent for depression treatment compound

Fri, 29 May 2026 08:41:16 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) announced the publication of a Japanese patent application for its proprietary compositions containing 5-Methoxy-2-aminoindan (MEAI) for depression treatment, according to a company statement.

The Vancouver-based clinical-stage biotech company describes MEAI as a non-hallucinogenic molecule designed as an alternative to traditional antidepressants and psychedelic-based therapies. The filing adds to Clearmind's intellectual property portfolio, which includes 19 patent families and 31 granted patents.

Japan has approximately 3 million diagnosed cases of major depressive disorder, the company stated. The global anxiety and depression treatment market is estimated at $16-22.65 billion in 2025, with projections reaching $19-30 billion by 2030-2031.

Clearmind is

Form 6-K Clearmind Medicine Inc. For: May 29

Fri, 29 May 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260529/26571125.html

Form 6-K Clearmind Medicine Inc. For: May 29

Fri, 29 May 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260529/26571125.html

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Fri, 29 May 2026 08:32:00 -0400

Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a Japanese Patent Application for its proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression.

This advancement strengthens Clearmind’s robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company’s flagship non-hallucinogenic molecule, is designed to offer a safer, more accessible alternative to traditional antidepressants and

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Fri, 29 May 2026 08:32:00 -0400

Form 6-K Clearmind Medicine Inc. For: May 26

Tue, 26 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260526/26546479.html

Form 6-K Clearmind Medicine Inc. For: May 26

Tue, 26 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260526/26546479.html

Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts

Tue, 26 May 2026 08:25:29 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) received approval from the Johns Hopkins Medicine Institutional Review Board to advance its Phase I/II clinical trial of CMND-100 to Parts B and C, the company announced May 26.

The multicenter study examines single and multiple dose tolerability, safety and pharmacokinetics of CMND-100 in healthy volunteers and subjects with alcohol use disorder. The approval permits the company to proceed with the next phases of the trial following completion of earlier stages.

CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what

Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts

Tue, 26 May 2026 08:25:29 -0400

CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts